You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 12, 2024

~ Buy the INGREZZA (valbenazine tosylate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR INGREZZA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Ingrezza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03325010 ↗ Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed Neurocrine Biosciences Phase 2 2017-10-05 This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric subjects with TS.
NCT03444038 ↗ Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Completed Neurocrine Biosciences Phase 2 2018-02-08 This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.
NCT03530293 ↗ Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Terminated Neurocrine Biosciences Phase 2 2018-04-16 This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.
NCT03732534 ↗ Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome Terminated Neurocrine Biosciences Phase 2 2018-10-17 This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study.
NCT05157100 ↗ Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia Enrolling by invitation The Orthopedic Foundation Phase 4 2021-10-19 STUDY OF INGREZZA (VALBENAZINE) FOR THE TREATMENT OF CERVICAL DYSTONIA
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ingrezza

Condition Name

Condition Name for Ingrezza
Intervention Trials
Tourette Syndrome 4
Cervical Dystonia 1
Trichotillomania (Hair-Pulling Disorder) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ingrezza
Intervention Trials
Tourette Syndrome 4
Syndrome 4
Torticollis 1
Dystonic Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ingrezza

Trials by Country

Trials by Country for Ingrezza
Location Trials
United States 65
Puerto Rico 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ingrezza
Location Trials
Texas 4
Illinois 4
Florida 4
Connecticut 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ingrezza

Clinical Trial Phase

Clinical Trial Phase for Ingrezza
Clinical Trial Phase Trials
Phase 4 1
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ingrezza
Clinical Trial Phase Trials
Terminated 2
Completed 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ingrezza

Sponsor Name

Sponsor Name for Ingrezza
Sponsor Trials
Neurocrine Biosciences 5
The Orthopedic Foundation 1
Michael Bloch 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ingrezza
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.